UGT1A1 genotype-guided dosing of irinotecan : time to prioritize patient safety
Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 24(2023), 8 vom: 01. Juni, Seite 435-439 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Peeters, Sofía Lj [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7673326042 |
|---|
| Anmerkungen: |
Date Completed 09.08.2023 Date Revised 10.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2023-0096 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359705782 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359705782 | ||
| 003 | DE-627 | ||
| 005 | 20231226081438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2023-0096 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM359705782 | ||
| 035 | |a (NLM)37470120 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Peeters, Sofía Lj |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a UGT1A1 genotype-guided dosing of irinotecan |b time to prioritize patient safety |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2023 | ||
| 500 | |a Date Revised 10.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a PGx | |
| 650 | 4 | |a UGT1A1 | |
| 650 | 4 | |a irinotecan | |
| 650 | 4 | |a personalized medicine | |
| 650 | 4 | |a pharmacogenetics | |
| 650 | 4 | |a pharmacogenomics | |
| 650 | 4 | |a precision dosing | |
| 650 | 4 | |a pretreatment | |
| 650 | 7 | |a Irinotecan |2 NLM | |
| 650 | 7 | |a 7673326042 |2 NLM | |
| 650 | 7 | |a Camptothecin |2 NLM | |
| 650 | 7 | |a XT3Z54Z28A |2 NLM | |
| 650 | 7 | |a Glucuronosyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.4.1.17 |2 NLM | |
| 700 | 1 | |a Deenen, Maarten J |e verfasserin |4 aut | |
| 700 | 1 | |a Thijs, Anna Mj |e verfasserin |4 aut | |
| 700 | 1 | |a Hulshof, Emma C |e verfasserin |4 aut | |
| 700 | 1 | |a Mathijssen, Ron Hj |e verfasserin |4 aut | |
| 700 | 1 | |a Gelderblom, Hans |e verfasserin |4 aut | |
| 700 | 1 | |a Guchelaar, Henk-Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Swen, Jesse J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 24(2023), 8 vom: 01. Juni, Seite 435-439 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:8 |g day:01 |g month:06 |g pages:435-439 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2023-0096 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 8 |b 01 |c 06 |h 435-439 | ||